OncoMatch/Clinical Trials/NCT07699276

Steroid Sparing Regimen With Olanzapine and Palonosetron for Emetic Prevention for High Dose Cisplatin

Is NCT07699276 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies dexamethasone sparing for cancer (solid tumors).

Phase 2RecruitingMahidol UniversityNCT07699276Data as of Sep 2026Location: Thailand

Treatment: dexamethasone sparing — A phase II study evaluating dexamethasone sparing regimen with olanzapine and palonosetron for patients receiving high dose cisplatin to prevent chemotherapy induced nausea and vomiting

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

dexamethasone sparing

Cancer type

Tumor Agnostic

Lab requirements

Kidney function

serum creatinine clearance less than 50 ml/min

Liver function

AST/ ALT > 2.5x

AST/ ALT > 2.5x or serum creatinine clearance less than 50 ml/min

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT07699276 currently recruiting?

Yes, this trial is currently recruiting patients.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify